Loading…
Vaidya Sane Ayurved Laboratories (MADHAVBAUG)₹141.00+1.44%Medical Equipment & Supplies
In the Mar 2026 quarter (consolidated), Vaidya Sane Ayurved Laboratories reported sales of ₹56.93 Cr, up 18.8% from Mar 2025, and net profit of ₹4.01 Cr, up 33.2% year on year. For the year to Mar 2026, sales were ₹107 Cr and net profit ₹9.01 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 53.90 | 50.89 | 47.94 | 41.94 | 47.94 | 49.89 | 56.93 |
| Expenses | 49.86 | 47.86 | 45.87 | 35.87 | 39.88 | 40.85 | 49.85 |
| Operating Profit | 4.01 | 3.01 | 2.01 | 6.02 | 9.02 | 9.01 | 7.01 |
| OPM % | 7.0% | 5.0% | 3.8% | 14.0% | 18.1% | 17.1% | 12.0% |
| Other Income | 0.99 | 0.99 | 0.99 | 0.99 | 0.00 | 0.99 | 0.99 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | 1.01 |
| Depreciation | 0.99 | 1.99 | 1.99 | 1.99 | 1.99 | 2.99 | 2.99 |
| Profit before tax | 3.01 | 2.01 | 1.01 | 5.01 | 5.01 | 6.01 | 4.01 |
| Tax % | 23.0% | 25.0% | 37.0% | 21.0% | 34.0% | 25.0% | 4.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | −0.80 | 0.00 | 0.00 |
| Net Profit | 2.01 | 1.01 | 1.01 | 4.01 | 3.01 | 5.01 | 4.01 |
| EPS (Rs) | 2.00 | 1.13 | 0.77 | 3.59 | 3.22 | 4.60 | 3.97 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 98.83 | 98.87 | 89.88 | 107 |
| Expenses | 90.75 | 94.73 | 75.77 | 90.72 |
| Operating Profit | 9.02 | 5.01 | 13.03 | 15.02 |
| OPM % | 9.0% | 4.5% | 15.1% | 14.0% |
| Other Income | 0.99 | 1.99 | 0.99 | 1.99 |
| Interest | 1.01 | 0.00 | 0.00 | 1.01 |
| Depreciation | 2.99 | 2.99 | 3.99 | 5.99 |
| Profit before tax | 6.01 | 3.01 | 10.02 | 11.03 |
| Tax % | 25.0% | 30.0% | 28.0% | 17.0% |
| Exceptional items | 0.00 | 0.47 | −0.88 | 0.00 |
| Net Profit | 5.01 | 2.01 | 7.01 | 9.01 |
| EPS (Rs) | 4.60 | 1.89 | 6.82 | 8.57 |
| Dividend payout % | 5.0% | 0.0% | 0.0% | 0.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 10.97 | 10.98 | 10.97 | 10.97 |
| Reserves | 30.01 | 45.01 | 52.04 | 77.01 |
| Borrowings | 0.00 | 1.99 | 0.99 | 2.99 |
| Other Liabilities | 14.01 | 12.05 | 13.05 | 14.00 |
| Total Liabilities | 54.99 | 70.03 | 77.05 | 105 |
| Fixed Assets | 21.06 | 28.11 | 34.13 | 35.15 |
| CWIP | 1.99 | 1.99 | 0.99 | 1.99 |
| Investments | 14.96 | 17.95 | 20.94 | 39.88 |
| Other Assets | 16.98 | 20.98 | 19.99 | 27.95 |
| Inventories | 3.42 | 4.12 | 3.77 | 3.66 |
| Trade receivables | 6.00 | 6.06 | 7.55 | 10.25 |
| Cash & equivalents | 1.75 | 2.36 | 2.35 | 0.43 |
| Total Assets | 54.99 | 70.03 | 77.05 | 105 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | 0.00 | −0.99 | 10.99 | 4.99 |
| Cash from investing activity | 0.99 | −12.97 | −9.99 | −23.96 |
| Cash from financing activity | −0.99 | 14.95 | −0.99 | 16.93 |
| Net cash flow | −1.01 | 1.01 | 0.00 | −2.01 |
| Capex | 6.97 | 11.12 | 8.43 | 7.86 |
| Free cash flow | −6.99 | −12.01 | 2.01 | −2.01 |
| CFO / OP % | 31.0% | −9.0% | 93.0% | 49.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 23 | 23 | 32 | 36 |
| Inventory days | — | 58 | 82 | 70 |
| Days payable | — | 101 | 149 | 127 |
| Cash conversion cycle | 23 | −19 | −36 | −20 |
| Working capital days | −2 | 5 | 7 | 112 |
| ROCE % | — | 6.0% | 18.1% | 15.0% |
For the Mar 2026 quarter, Vaidya Sane Ayurved Laboratories reported sales of ₹56.93 Cr, up 18.8% year on year and net profit of ₹4.01 Cr, up 33.2% year on year. The operating margin was 12.0%.
Vaidya Sane Ayurved Laboratories' sales for the year to Mar 2026 were ₹107 Cr.
Net profit for the year to Mar 2026 was ₹9.01 Cr. Earnings per share over the same trailing period were ₹8.57.
Vaidya Sane Ayurved Laboratories reported borrowings of ₹2.99 Cr at Mar 2026, against cash and equivalents of ₹0.43 Cr.
Cash from operations was ₹4.99 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹2.01 Cr.